Tag: MDS

E5-2666v4-x10drl-ct-2023-06-07 Lammps Performance – OpenBenchmarking.org

Intel Xeon E5-2666 v4 testing with a Supermicro X10DRL-CT v0123456789 (3.2 BIOS) and NVIDIA GeForce GTX 1080 Ti 11GB on Ubuntu 20.04 via the Phoronix Test Suite. Compare your own system(s) to this result file with the Phoronix Test Suite by running the command: phoronix-test-suite benchmark 2306074-NE-E52666V4X88 Intel Xeon E5-2666…

Continue Reading E5-2666v4-x10drl-ct-2023-06-07 Lammps Performance – OpenBenchmarking.org

Assessing Methylation-Based Sequencing as a Risk-Stratifying Tool in MDS

Methylation-based sequencing appears to be a viable risk-assessment tool for myelodysplastic syndromes (MDS), according to a study presented at the 2023 American Society of Clinical Oncology Annual Meeting. “MDS risk stratification is key for [making] optimal treatment decisions. DNA methylation is associated with MDS biology due to frequent somatic mutations…

Continue Reading Assessing Methylation-Based Sequencing as a Risk-Stratifying Tool in MDS

A familial SAMD9 variant present in pediatric myelodysplastic syndrome

Cold Spring Harb Mol Case Stud. 2023 Apr; 9(2): a006256. ,1,2 ,1,2 ,1,2 ,2,3 ,4 and 1,2 Mahvish Q. Rahim 1Pediatric Hematology Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA; 2Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA; April Rahrig 1Pediatric Hematology Oncology,…

Continue Reading A familial SAMD9 variant present in pediatric myelodysplastic syndrome

Biogen and Denali Terminate Phase 3 LIGHTHOUSE Study of BIIB122 in LRRK2-related Parkinson Disease

Samantha B. Haeberlein, PhD Biogen and Denali have announced that they are discontinuing a portion of the clinical development program for BIIB122 (also known as DNL151), an investigational small molecule inhibitor of LRRK2 in development for the treatment of Parkinson disease (PD). As a result of this decision, the phase…

Continue Reading Biogen and Denali Terminate Phase 3 LIGHTHOUSE Study of BIIB122 in LRRK2-related Parkinson Disease

BIAL announces positive results from phase 3 study in early levodopa treated Parkinson’s disease patients without motor complications

Porto, Portugal, June 5th 2023 – BIAL today announces positive topline results of its phase 3 EPSILON (Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe) study evaluating opicapone 50mg in adult levodopa treated Parkinson’s Disease (PD) patients without motor complications. In the EPSILON study, opicapone 50 mg was found to be statistically…

Continue Reading BIAL announces positive results from phase 3 study in early levodopa treated Parkinson’s disease patients without motor complications

Phase 3 Findings Demonstrate Durable Benefit With Imetelstat For Patients With R/R MDS

Imetelstat, a first-in-class telomerase inhibitor, decreased transfusion dependence and increased hemoglobin counts for patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome (MDS) that is relapsed or refractory to erythropoiesis stimulating agents (ESAs), according to findings from the phase 3 IMerge trial (NCT02598661) presented during the 2023 ASCO Annual Meeting.1…

Continue Reading Phase 3 Findings Demonstrate Durable Benefit With Imetelstat For Patients With R/R MDS

Detection of Plasmodium simium gametocytes in non-human primates from the Brazilian Atlantic Forest | Malaria Journal

WHO. World malaria report 2022. Geneva: World Health Organization; 2023. Google Scholar  Ministério da Saúde/Secretaria de Vigilância em Saúde. Malária 2021. Boletim Epidemiológico. Número especial. Brasília: MS/SVS; 2021. 100 pp. Melo JO, Padilha MAO, Barbosa RTA, Alonso WJ, Vittor AY, Laporta GZ. Evaluation of the malaria elimination policy in Brazil:…

Continue Reading Detection of Plasmodium simium gametocytes in non-human primates from the Brazilian Atlantic Forest | Malaria Journal

Imetelstat Displays Significant Efficacy in R/R Myelodysplastic Syndrome

Statistically significant and clinically meaningful efficacy has been demonstrated with imetelstat, a first-in-class direct and competitive telomerase inhibitor imetelstat, in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome (MDS) that is relapsed or refractory to erythropoiesis stimulating agents (ESAs).1 Findings come from the phase 3 IMerge trial (NCT02598661), which…

Continue Reading Imetelstat Displays Significant Efficacy in R/R Myelodysplastic Syndrome

Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS

Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome (MDS) that is relapsed or refractory to erythropoiesis stimulating agents (ESAs),according to findings from the phase 3 IMerge trial (NCT02598661) presented during…

Continue Reading Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS

Geron Reports Durable Continuous Transfusion Independence With Imetelstat in IMerge Phase 3 Lower Risk MDS Patients

MT Newswires 2023 All news about GERON CORPORATION Analyst Recommendations on GERON CORPORATION Sales 2023 0,16 M – – Net income 2023 -210 M – – Net cash 2023 66,2 M – – P/E ratio 2023 -9,09x Yield 2023 – Capitalization 1 720 M 1 720 M – EV / Sales 2023 10…

Continue Reading Geron Reports Durable Continuous Transfusion Independence With Imetelstat in IMerge Phase 3 Lower Risk MDS Patients

Advanced Degree Holders – Management Consulting

Advanced degree holders (JDs, MDs, and PhDs) bring unique and valuable perspectives to our casework. Your expertise, eagerness to learn, and problem-solving abilities will drive change for our clients from day one—but you won’t do it alone. You’ll join a collaborative and supportive network of digital innovators to deliver extraordinary…

Continue Reading Advanced Degree Holders – Management Consulting

Baraminic Analysis of Crocodylia Based on Mitochondrial DNA Similarity

Introduction The reptilian order Crocodylia is comprised of alligators, caimans, crocodiles, and gharials. These animals live in North and South America, Africa, India, Southeast Asia, and northern Australia. Crocodylia includes the families Alligatoridae, Crocodylidae, and Gavialidae. The latter two families belong to the clade Longirostres, since they…

Continue Reading Baraminic Analysis of Crocodylia Based on Mitochondrial DNA Similarity

Geron: Ready To Face The Competition With Imetelstat In Lower-Risk MDS (GERN)

efks/iStock via Getty Images Geron Corporation (NASDAQ:GERN) is developing imetelstat for lower risk myelodysplastic syndromes (LR-MDS) and myelofibrosis (MF). While GERN announced success in its phase 3 IMerge study in LR-MDS in January 2023, the MF indication isn’t as close to approval with an interim analysis not expected from a…

Continue Reading Geron: Ready To Face The Competition With Imetelstat In Lower-Risk MDS (GERN)

Geron Announces Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial and Promising Results from REQORSA and Tagrisso Combination Trial

On May 25, 2023, Geron, a leading biopharmaceutical company, made a significant announcement regarding its latest research findings. The company revealed that it will be presenting Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial at the 2023 American Society of Clinical Oncology Annual Meeting. The IMerge Phase 2/3…

Continue Reading Geron Announces Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial and Promising Results from REQORSA and Tagrisso Combination Trial

2023-05-25 | NYSE:BMY | Press Release

Results from Phase 3 COMMANDS study, selected for ASCO’s official press program,show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent hemoglobin increase vs. epoetin alfa, including in clinically relevant subgroups Reblozyl demonstrated a durable response, with nearly 2.5 years median transfusion independence, 1 year…

Continue Reading 2023-05-25 | NYSE:BMY | Press Release

PLINK not converting entire vcf to bed file

PLINK not converting entire vcf to bed file 0 here is my code : [ethan.kreuzer@hydra1 2_Population_stratification]$ plink –vcf ALL.2of4intersection.20100804.genotypes.vcf.gz –make-bed –out ALL.2of4intersection.20100804.genotypes [mii] Please select a module to run plink: MODULE PARENT(S) 1 plink/1.9b_6.21-x86_64 StdEnv/2020 2 plink/1.07 nixpkgs/16.09 intel/2018.3 3 plink/1.9b_5.2-x86_64 nixpkgs/16.09 4 plink/1.9b_4.1-x86_64 nixpkgs/16.09 Make a selection (1-4, q…

Continue Reading PLINK not converting entire vcf to bed file

NK Cell Therapy Pipeline Insight

PRESS RELEASE Published May 24, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

Continue Reading NK Cell Therapy Pipeline Insight

Roundup trial: Oncologist tells jury woman’s blood cancer unlikely to return

An oncologist appearing as a defense expert witness for Monsanto told a jury on Monday that Plaintiff Sharlean Gordon’s cancer, which she alleges was caused by the use of weed killer Roundup, is cured and unlikely to recur. Plaintiff attorneys responded that Gordon’s suffering over 16 years could not be minimized….

Continue Reading Roundup trial: Oncologist tells jury woman’s blood cancer unlikely to return

IAV Trivandrum Virology/Bioinformatics Scientist Job Openings

Institute of Advanced Virology (IAV) is an autonomous institution under Department of Science & Technology, Government of Kerala and focuses on cutting-edge research initiatives in virology. IAV envisions to function through the eight departments in specific areas of Virology. In order to strengthen the research activities, we seek extremely dynamic…

Continue Reading IAV Trivandrum Virology/Bioinformatics Scientist Job Openings

Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Senti Biosciences, Inc. Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies…

Continue Reading Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

How to generate BED files with 3D coordinates?

How to generate BED files with 3D coordinates? 1 I’m analyzing some HiC data for the 1st time. I need to generate a 3D model of the data. For visualization, I require the format to be in .pdb or .g3d (as described in g3d.readthedocs.io/en/latest/g3dtools.html). I have been going through a…

Continue Reading How to generate BED files with 3D coordinates?

OMICSEDGE FORMS STRATEGIC PARTNERSHIP WITH ALMADEN GENOMICS TO STREAMLINE DRUG DISCOVERY

MIAMI and DALLAS , May 18, 2023 /PRNewswire/ — OmicsEdge has launched an industry leading drug discovery service that leverages Almaden’s g.nome™ platform to streamline the iteration process. The service makes it easy for labs to conduct a quick analysis of a patient or trial participant’s medical condition and genomics,…

Continue Reading OMICSEDGE FORMS STRATEGIC PARTNERSHIP WITH ALMADEN GENOMICS TO STREAMLINE DRUG DISCOVERY

Chinese Phase 3 Trial of Roxadustat in Non-Myeloid Malignancies Meets Primary End Point

Roxadustat proved to be noninferior to recombinant erythropoietin alfa (Sepo) with regard to change in hemoglobin level from baseline to an average level during weeks 9 to 13 in patients receiving concurrent chemotherapy for non-myeloid malignancies in China, meeting the primary end point of an ongoing phase 3 trial (NCT05301517).1…

Continue Reading Chinese Phase 3 Trial of Roxadustat in Non-Myeloid Malignancies Meets Primary End Point

GILEAD AND KITE ONCOLOGY TO SHOWCASE ADVANCES ACROSS THE PIPELINE AIMING TO ADDRESS UNMET NEEDS IN CANCER CARE AT ASCO 2023

GILEAD  AND  KITE  ONCOLOGY  TO  SHOWCASE  ADVANCES  ACROSS  THE  PIPELINE  AIMING  TO  ADDRESS  UNMET  NEEDS  IN  CANCER  CARE  AT  ASCO  2023 – Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Haematologic, Genitourinary, Gastrointestinal, Gynaecological and Other Solid Tumours –   –…

Continue Reading GILEAD AND KITE ONCOLOGY TO SHOWCASE ADVANCES ACROSS THE PIPELINE AIMING TO ADDRESS UNMET NEEDS IN CANCER CARE AT ASCO 2023

Pyrimidine Nucleoside – an overview

Peripheral neuropathy in nuclear encoded mitochondrial genes A peripheral neuropathy may be a prominent and initial symptom in pyruvate dehydrogenase complex E1alpha (MIM *300502) deficiency mimicking a postinfectious subacute polyneuropathy (Bonne et al., 1990; Chabrol et al., 1994) and is part of the syndromic spectrum in several nuclear encoded mitochondrial…

Continue Reading Pyrimidine Nucleoside – an overview

How to run detectron2, as python embedded code in C++, on GPU?

I want to run detectron2 prediction as a Python Code embedded in a WebRTC C++ code. I am using webrtc-streamer as a C++ server in which I want to embed detectron2 Python code to call a prediction function. Everything works fine when I run the executable of webrtc-streamer and call…

Continue Reading How to run detectron2, as python embedded code in C++, on GPU?

Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 | Business

FOSTER CITY, Calif.–(BUSINESS WIRE)–May 11, 2023– Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that five abstracts related to imetelstat, a first-in-class telomerase inhibitor, have been accepted at the European Hematology Association (EHA) Annual Meeting taking place from June 8-11, 2023 in Frankfurt, Germany and virtually. The…

Continue Reading Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 | Business

Geron: Updates Ahead Of Q1 2023 Earnings (NASDAQ:GERN)

breakermaximus/iStock via Getty Images Investment Overview Geron (NASDAQ:GERN) will announce its Q1 2023 results this Thursday, May 11th. I last covered the company in a Seeking Alpha post back in mid-March, issuing a “HOLD” recommendation. Let’s recap the investment thesis. Geron’s lead and only asset is Imetelstat – a first-in-class…

Continue Reading Geron: Updates Ahead Of Q1 2023 Earnings (NASDAQ:GERN)

Senti Bio Announces First Quarter 2023 Results and Pipeline

– New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 – – Initial collaboration data with BlueRock and Spark to be presented at ASGCT, validating that Senti’s Gene Circuit enabled cell platform…

Continue Reading Senti Bio Announces First Quarter 2023 Results and Pipeline

2023-05-08 | NDAQ:FGEN | Press Release

• Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value •Entered Into Exclusive License for FOR46 with Fortis Therapeutics SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today…

Continue Reading 2023-05-08 | NDAQ:FGEN | Press Release

FibroGen Reports First Quarter 2023 Financial Results

• Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into Exclusive License for FOR46 with Fortis Therapeutics SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today reported…

Continue Reading FibroGen Reports First Quarter 2023 Financial Results

Amplification Biases and Consistent Recovery of Loci in a Double-Digest RAD-seq Protocol | PLOS ONE – Molecular Biology Protocol – Restriction Digest of Plasmid …

Abstract A waxing variety of “genotype-by-sequencing” (GBS) methods use restriction enzymes and high throughput DNA ordering to generation data for a set of genomic loci, allowing the simultaneous discovery press genotyping of thousands of polymorphisms in a set of multiplexed samples. We evaluated a “double-digest” restriction-site associated DNA sequencing (ddRAD-seq)…

Continue Reading Amplification Biases and Consistent Recovery of Loci in a Double-Digest RAD-seq Protocol | PLOS ONE – Molecular Biology Protocol – Restriction Digest of Plasmid …

Roxadustat Misses Mark as Anemia Treatment in Transfusion-Dependent, Lower-risk MDS

The phase 3 MATTERHORN trial (NCT03263091) examining roxadustat (Evrenzo) as an anemia treatment in patients with transfusion-dependent, lower-risk myelodysplastic syndrome (MDS) did not meet its primary end point, according to an announcement from FibroGen, Inc.1 Specifically, data indicated that 47.5% of those who received roxadustat (n = 140) achieved red…

Continue Reading Roxadustat Misses Mark as Anemia Treatment in Transfusion-Dependent, Lower-risk MDS

FibroGen Announces Results for MATTERHORN Phase 3 Trial By Investing.com

FibroGen, Inc. (NASDAQ:) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplastic syndromes (MDS) did not meet its primary efficacy endpoint. The proportion of patients who achieved red blood cell transfusion independence in the first 28 weeks…

Continue Reading FibroGen Announces Results for MATTERHORN Phase 3 Trial By Investing.com

FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)Study Did Not Meet Primary Endpoint

SAN FRANCISCO, May 05, 2023 (GLOBE NEWSWIRE) —FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplastic syndromes (MDS) did not meet its primary efficacy endpoint. The proportion of patients who achieved red blood cell…

Continue Reading FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)Study Did Not Meet Primary Endpoint

Agios Reports Business Highlights and First Quarter 2023 Financial Results

– On Track for PYRUKYND ® (mitapivat) Data Readouts of the Phase 2 Portion of the RISE UP Study in Sickle Cell Disease in Mid-2023 and the Phase 3 ENERGIZE and ENERGIZE-T Studies in Thalassemia in 2024 – U.S. PYRUKYND ® Net Revenue of $5.6 Million in Q1; $1.0 Billion…

Continue Reading Agios Reports Business Highlights and First Quarter 2023 Financial Results

FibroGen Announces Results for MATTERHORN, a Phase 3

SAN FRANCISCO, May 05, 2023 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplastic syndromes (MDS) did not meet its primary efficacy endpoint. The proportion of patients who achieved red blood…

Continue Reading FibroGen Announces Results for MATTERHORN, a Phase 3

AAN 2023: IPX203 still safe, effective in Parkinson’s extension trial

IPX203, Amneal Pharmaceuticals‘ investigational extended-release carbidopa/levodopa (CD/LD) treatment for Parkinson’s disease, continued to exhibit a favorable safety and efficacy profile during the open-label extension part of the Phase 3 RISE-PD trial. “IPX203 remained as efficacious and safe as it was shown during the RISE-PD study, and the vast majority of…

Continue Reading AAN 2023: IPX203 still safe, effective in Parkinson’s extension trial

Postdoctoral Fellow position in Computational Biology / Bioinformatics

Ledig stilling på Universitetet i Oslo Blindern og Urbygningen (Foto: Wikimedia og Colourbox) Deadline: 22.05.2023 Universitetet i Oslo The University of Oslo is Norway’s oldest and highest ranked educational and research institution, with 28 000 students and 7000 employees. With its broad range of academic disciplines and internationally recognised research…

Continue Reading Postdoctoral Fellow position in Computational Biology / Bioinformatics

Query in indexing human genome

Hello , I have to do RNAseq analysis of human cancer cell lines , for that I need to index human genome , as a refrence genome. I index the human genome gff file from thr NCBI.. during some lecture I have heard that ncbi human genome file has some…

Continue Reading Query in indexing human genome

Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial | Illinois

Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial | Illinois | wsiltv.com We recognize you are attempting to access this website from a country belonging to the European Economic Area (EEA) including the…

Continue Reading Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial | Illinois

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

GAITHERSBURG, Md. and SHANGHAI, April 24, 2023 /PRNewswire/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in a Phase 3 registrational trial (ClinicalTrials.gov Identifier: NCT05709093) in China for patients with higher-risk myelodysplastic syndrome…

Continue Reading I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

I5-cp2k Benchmarks – OpenBenchmarking.org

Intel Core i5-12500T testing with a HP 894F (U21 Ver. 02.06.00 BIOS) and llvmpipe on Rocky Linux 8.7 via the Phoronix Test Suite. Compare your own system(s) to this result file with the Phoronix Test Suite by running the command: phoronix-test-suite benchmark 2304214-NE-I5CP2K70437 HP Mini i5-12500T cp2k Processor: Intel Core…

Continue Reading I5-cp2k Benchmarks – OpenBenchmarking.org

I5-lammps Performance – OpenBenchmarking.org

Intel Core i5-12500T testing with a HP 894F (U21 Ver. 02.06.00 BIOS) and llvmpipe on Rocky Linux 8.7 via the Phoronix Test Suite. Compare your own system(s) to this result file with the Phoronix Test Suite by running the command: phoronix-test-suite benchmark 2304206-NE-I5LAMMPS261 HP i5-12500T Rocky 8 LAMMPS Processor: Intel…

Continue Reading I5-lammps Performance – OpenBenchmarking.org

Vai-lammps Performance – OpenBenchmarking.org

AMD Ryzen Threadripper 1950X 16-Core testing with a ASUS PRIME X399-A (1203 BIOS) and llvmpipe on Linuxmint 20.3 via the Phoronix Test Suite. Compare your own system(s) to this result file with the Phoronix Test Suite by running the command: phoronix-test-suite benchmark 2304201-NE-VAILAMMPS89 Threadripper 1950X lammps Processor: AMD Ryzen Threadripper…

Continue Reading Vai-lammps Performance – OpenBenchmarking.org

NK Cell Therapy Pipeline Booms as 100+ Companies likely to Enter in the Treatment Domain

PRESS RELEASE Published April 18, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

Continue Reading NK Cell Therapy Pipeline Booms as 100+ Companies likely to Enter in the Treatment Domain

Senti Bio to Participate in Upcoming Investor Conferences

Senti Biosciences, Inc. SOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences: Bank of America 2023 Global Healthcare…

Continue Reading Senti Bio to Participate in Upcoming Investor Conferences

Abstract LB130: Single-cell multiomics analysis of myelodysplastic syndrome predicts clinical response to DNA methylation inhibitor therapy | Cancer Research

Epigenetic alterations, such as DNA methylation aberrations, are a hallmark of human cancer. This observation has led to the assessment of hypomethylating agents (HMAs) as potential drugs to treat oncological patients, being considered the clinical approval of these pharmacological compounds in the therapy of myeloid malignancies as one of the…

Continue Reading Abstract LB130: Single-cell multiomics analysis of myelodysplastic syndrome predicts clinical response to DNA methylation inhibitor therapy | Cancer Research

Imetelstat Displays Early Efficacy in Myelofibrosis; Phase 3 Trial Is Underway

Patients with myelofibrosis have limited effective treatment options and a poor prognosis. However, the first-in-class telomerase inhibitor imetelstat is poised to expand the treatment armamentarium should it prove safe and effective in the newly initiated phase 3 IMpactMF trial (NCT04576156).1,2 Three FDA-approved treatment options are available for myelofibrosis: ruxolitinib (Jakafi),…

Continue Reading Imetelstat Displays Early Efficacy in Myelofibrosis; Phase 3 Trial Is Underway

6 protein degradation companies you should know about in 2023

Protein degradation platforms have revolutionized drug discovery aimed at undruggable targets. Biopharmaceutical companies around the world have engaged in the protein degradation field, with the hope of leveraging the capabilities of these coumpounds to successfully design drugs to treat diseases like cancer and neurodegenerative disorders. The discovery of the ubiquitin…

Continue Reading 6 protein degradation companies you should know about in 2023

Annovis And Buntanetap: Asymmetric Risk/Reward Ahead Of Parkinson’s Data Readout (ANVS)

Ralwel Update as of 12:00PM ET, 3/30/23: Annovis Phase 3 interim data presentation rescheduled to Saturday (1/1/23) due to scheduling issues at the AD/PD 2023 conference, according to sources. Not yet confirmed. Intro With an interim readout of Phase 3 Parkinson’s disease (PD) data due today (3/30/23) and shares finishing…

Continue Reading Annovis And Buntanetap: Asymmetric Risk/Reward Ahead Of Parkinson’s Data Readout (ANVS)

Research Assistant/Research Associate in Inflammation and Computational Biology job with KINGS COLLEGE LONDON

Job description This is an exciting opportunity to be a key member of a team that is researching the genomic origins of inflammatory disease and myeloid cancers.  We are studying clonal haematopoiesis or CHIP, where individuals acquire mutations in blood cells without apparent blood disease, and these mutations occur in…

Continue Reading Research Assistant/Research Associate in Inflammation and Computational Biology job with KINGS COLLEGE LONDON

Check Posts, Age, Salary, Qualification and How to Apply

DRDO Recruitment 2023: Check Posts, Age, Salary, Qualification and How to Apply DRDO Recruitment 2023: Defence Research and Development Organisation (DRDO) is looking eligible candidates for the post of Research Associate and Junior Research Fellowship (JRF). There are 09 vacant seats available for the mentioned post. As per the official…

Continue Reading Check Posts, Age, Salary, Qualification and How to Apply

As Use of Large Cancer Panels and Whole-Genome Sequencing Expands, Illumina Plans to Future-Proof NGS Interpretation and Reporting

Illumina is releasing a new cloud-based, customizable platform that enables tertiary analysis for clinical NGS data, which the company says will streamline interpretation and reporting for a diverse range of application areas. Through application programming interface (API)-based calls, the platform will allow labs to scale up their NGS applications and…

Continue Reading As Use of Large Cancer Panels and Whole-Genome Sequencing Expands, Illumina Plans to Future-Proof NGS Interpretation and Reporting

Integrating and optimizing genomic, weather, and secondary trait data for multiclass classification

1 Introduction Modern plant breeding programs are collecting an increasing amount of data of various types from several sources such as multiple secondary phenotypic traits (other than the main trait of interest), high-throughput phenotyping data, weather data, hyper-spectral images, and different types of -omics data such as genomics, transcriptomics, proteomics,…

Continue Reading Integrating and optimizing genomic, weather, and secondary trait data for multiclass classification

100+ Active Companies working to Develop 185+ Pipeline Therapies for NK Cell Therapy Treatment

PRESS RELEASE Published March 23, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

Continue Reading 100+ Active Companies working to Develop 185+ Pipeline Therapies for NK Cell Therapy Treatment

Karolinska Institute researchers discover new leukemia mechanism

Researchers at Lund University Faculty of Medicine in Sweden have determined a novel mechanism linking the metabolism of ribonucleic acids, RNA, to the development of leukemia in myelodysplastic syndrome patients, MDS. In a study published in the Molecular Cell journal, they explain what makes hematopoietic stem cells acquire malignant traits…

Continue Reading Karolinska Institute researchers discover new leukemia mechanism

What makes blood stem cells transform?

Researchers at Lund University Faculty of Medicine in Sweden have determined a novel mechanism linking the metabolism of ribonucleic acids, RNA, to the development of leukemia in myelodysplastic syndrome patients, MDS. In a study published in the Molecular Cell journal, they explain what makes hematopoietic stem cells acquire malignant traits…

Continue Reading What makes blood stem cells transform?

Big BCV (Biological Coefficient of Variation)

Big BCV (Biological Coefficient of Variation) – no sense to continue the analysis of differential gene expression? 2 Is it possible to perform differential gene expression analysis on data with such dispersion, BCV and MDSplot? (Fig. A, B) y_disp_design <- estimateDisp(y_filtered, design = design) y_disp_design$common.dispersion 0.3251901 Is it possible to…

Continue Reading Big BCV (Biological Coefficient of Variation)

Check Posts, Qualifications and How to Apply

DRDO INMAS Recruitment 2023: Check Posts, Qualifications and How to Apply DRDO INMAS Recruitment 2023: Defence Research and Development Organisation – Institute of Nuclear Medicine and Allied Sciences (DRDO INMAS) is inviting applications for eligible candidates for the Research Associate and Junior Research Fellowship post on a contract basis. As…

Continue Reading Check Posts, Qualifications and How to Apply

change the axis scale in mds plot

change the axis scale in mds plot 0 Hi, I was trying to calculate distance matrix from my dataset to generate aMultidimensional Scaling Plot. However, values generated from dist() function when I try to calculate the distance matrix are too high. There is a setting to modify it? d <-…

Continue Reading change the axis scale in mds plot

2023-02-27 | NDAQ:FGEN | Press Release

Topline Data from Five Pivotal Phase 3 Trials in 2023 Total Company Revenue $140.7 Million in 2022 Continued Strong Roxadustat Volume Growth in China SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2022 and provided…

Continue Reading 2023-02-27 | NDAQ:FGEN | Press Release

Faculty Spotlight: Bioinformatics

Faculty: Alexandra Maertens Program: Bioinformatics Spring-2 Course: RBIF 114: Molecular Profiling and Biomarker Discovery Education: PhD in Toxicology, Johns Hopkins Bloomberg School of Public Health Bio: Alexandra Maertens is an Assistant Scientist at the Center for Alternatives in Animal Testing at the Johns Hopkins Bloomberg School of Public Health and a consultant at…

Continue Reading Faculty Spotlight: Bioinformatics

NK Cell Therapy Pipeline Analysis Demonstrates Novel 100+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

PRESS RELEASE Published February 21, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

Continue Reading NK Cell Therapy Pipeline Analysis Demonstrates Novel 100+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

Early Data for Orca-T Cellular Therapy Provides Basis for Phase 3 Study in AML

The use of the precision cellular therapy Orca-T demonstrated promising efficacy effects at a median follow-up of 1 year in patients with acute leukemia or high-risk myelodysplastic syndrome (MDS) in an early analysis of a phase 1b and 2 study that have yet to be reported, according to data presented…

Continue Reading Early Data for Orca-T Cellular Therapy Provides Basis for Phase 3 Study in AML

Pfizer Announces Positive TALZENNA and XTANDI Combination Data from Phase 3 TALAPRO-2 Study

NEW YORK – Pfizer (NYSE: PFE) announced today positive results from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival compared to placebo plus XTANDI in men with metastatic…

Continue Reading Pfizer Announces Positive TALZENNA and XTANDI Combination Data from Phase 3 TALAPRO-2 Study

Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes

In general, more than half of MDS patients are diagnosed at age 75 years or older, and the incidence rate of MDS in patients under 50 years of age is as low as less than 1 per 100,000)3. The median number of gene mutations in patients with MDS has been found to…

Continue Reading Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes

Investigating ultrastructural morphology in… | F1000Research

Introduction MIRAGE syndrome (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital (gonadal) phenotypes, and enteropathy) (OMIM: 617053) is a well-established complex multisystem disorder caused by pathogenic gain-of-function variants in the gene SAMD9.1,2 Changes in this gene were first described in 2016 and to date more than 100 affected individuals have…

Continue Reading Investigating ultrastructural morphology in… | F1000Research

Phase 3 trial of buntanetap for Parkinson’s expands to Europe

A Phase 3 clinical trial of Annovis Bio‘s investigational oral treatment buntanetap in people with early-stage Parkinson’s disease now will open to patients in Europe. This expansion will add 48 new trial sites in Italy, Spain, Hungary, Poland and Germany, joining about 50 sites actively recruiting in the U.S. Overall, the Phase…

Continue Reading Phase 3 trial of buntanetap for Parkinson’s expands to Europe

how many axes to plot?

NMDS: how many axes to plot? 1 Hi all, I have a question on NMDS. I runned an NMDS on my data and it extracts 4 axes. I now have to plot my results, but I don’t know if I should plot all axes combination or just the first 2….

Continue Reading how many axes to plot?

finding error to run edgeR, error in ploting MDS and after that in model matrix also

finding error to run edgeR, error in ploting MDS and after that in model matrix also 0 library(edgeR) counts <- read.delim(“GSE116959_series_matrix.txt”, row.names = 1) head(counts) d0 <- DGEList(counts) d0 <- calcNormFactors(d0) d0 cutoff <- 1 drop <- which(apply(cpm(d0), 1, max) < cutoff) d <- d0[-drop,] dim(d) # number of genes…

Continue Reading finding error to run edgeR, error in ploting MDS and after that in model matrix also

Gromacs Test Result Benchmarks – OpenBenchmarking.org

Intel Xeon Gold 6414U testing with a Supermicro X13SET-G v1.02 and ASPEED on Ubuntu 22.04 via the Phoronix Test Suite. Compare your own system(s) to this result file with the Phoronix Test Suite by running the command: phoronix-test-suite benchmark 2301271-NE-GROMACSTE28 27 january Gromacs Processor: Intel Xeon Gold 6414U @ 2.00GHz…

Continue Reading Gromacs Test Result Benchmarks – OpenBenchmarking.org

Lammps Test Results For 27 January Benchmarks

Intel Xeon Gold 6414U testing with a Supermicro X13SET-G v1.02 and ASPEED on Ubuntu 22.04 via the Phoronix Test Suite. Compare your own system(s) to this result file with the Phoronix Test Suite by running the command: phoronix-test-suite benchmark 2301275-NE-LAMMPSTES54 Test 2 Processor: Intel Xeon Gold 6414U @ 2.00GHz (32…

Continue Reading Lammps Test Results For 27 January Benchmarks

Tumor microbiome linked to immunotherapy success in sarcoma patients

Soft tissue sarcomas intratumoral microbiome at diagnosis may link with prognosis. (A) Representative gross examination of extremity synovial sarcoma specimen; asterisk demonstrates tumor necrosis and arrow identifies an encased major artery. (B) Multidimensional scaling (MDS) plot based on mathematical distance of taxonomic divergence for pre-RT intratumoral microbiome by alpha diversity….

Continue Reading Tumor microbiome linked to immunotherapy success in sarcoma patients

Analysis of Phase 3 Trial of Parkinson’s Therapy Buntanetap Due

Annovis Bio anticipates an interim data analysis from a Phase 3 trial of its therapeutic candidate buntanetap in people with early-stage Parkinson’s disease will be possible by mid-year, based on current trial enrollment. By then, there will likely be enough patients who’ll have received at least two months of daily…

Continue Reading Analysis of Phase 3 Trial of Parkinson’s Therapy Buntanetap Due

ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON’S DISEASE

Strong enrollment in Phase 3 trial demonstrates continued executionInterim analysis expected in 2Q 2023 BERWYN, Pa., Jan. 25, 2023  /PRNewswire/ — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, today provided a patient enrollment update for the Company’s ongoing Phase 3 study…

Continue Reading ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON’S DISEASE

Annovis Bio Inc. (ANVS) Provides Update on Enrollment into Phase 3 Study of buntanetap

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, today provided a patient enrollment update for the Company’s ongoing Phase 3 study of buntanetap…

Continue Reading Annovis Bio Inc. (ANVS) Provides Update on Enrollment into Phase 3 Study of buntanetap

Phase 3 MEDALIST Trial Results Show ‘Red Blood Cell Transfusion Independence for Substantial Period of Time’ in LR-MDS

Pharmacy Times® interviewed Uwe Platzbecker, MD, director of the Clinic and Polyclinic, Hematology, Cell Therapy, and Hemostaseology, Leipzig University Hospital, on the poster presentation titled “Multiple Episodes of Transfusion Independence with Luspatercept [Reblozyl; Celgene Corporation] Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes [LR-MDS] from…

Continue Reading Phase 3 MEDALIST Trial Results Show ‘Red Blood Cell Transfusion Independence for Substantial Period of Time’ in LR-MDS

Dosing Begins for LIGHTHOUSE, Parkinson’s Clinical Trial of BIIB122

Dosing has begun in LIGHTHOUSE, a Phase 3 clinical trial testing BIIB122 — an experimental inhibitor of LRRK2 being developed by Biogen and Denali Therapeutics — in patients with early-stage Parkinson’s disease. The study (NCT05418673), underway at two clinical sites in Colorado and Florida, is recruiting up to 400 patients…

Continue Reading Dosing Begins for LIGHTHOUSE, Parkinson’s Clinical Trial of BIIB122

Microarray DEG scatterplot

Hi, I have found that my selected gene, probe I.D 201667_at is differentially expressed between WDLPS and DDLPS tumour tissue samples after performing microarray DEG analysis. Instead of just a p value in a table format: Probe I.D “201667_at” logFC 10.8205874181535 AveExpr 10.6925705768407 t 82.8808890739766 P.Value 3.10189446528995e-88 adj.P Val 3.10189446528995e-88…

Continue Reading Microarray DEG scatterplot

Patrick Murphy Bulk RNA-Seq – HackMD

Patrick Murphy Bulk RNA-Seq – HackMD        owned this note   Published Linked with GitHub — title: ‘Patrick Murphy Bulk RNA-Seq’ disqus: hackmd — Patrick Murphy bulk RNA-Seq Analysis === ## Table of Contents [TOC] ## 1. Introduction This is a bulk RNA-Seq project, which includes human data….

Continue Reading Patrick Murphy Bulk RNA-Seq – HackMD

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the ‘Company’), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced an update on its financial results and recent business developments for the first half ended June…

Continue Reading Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

I have a query regarding differential gene expression using limma-voom.

I have a query regarding differential gene expression using limma-voom. 1 @28946033 Last seen 1 day ago India I used the following pipeline for RNA Seq Analysis Fastq-Trimmomatic- Hisat2(gtf file was annotated)-featurecounts After featurecounts I tried to do limmavoom, but I get error saying this An error occurred with this…

Continue Reading I have a query regarding differential gene expression using limma-voom.

Genetic diversity of loquat (Eriobotrya japonica) revealed using RAD-Seq SNP markers & More Science News

Our research analyzed the genetic diversity of 95 cultivars and strains of loquat collected from everywhere in the world. On the premise of the evaluation of the inhabitants construction of 19 Chinese loquat cultivars and strains by RAD-Seq, Hubei Province in China has been recommended as the middle of origin…

Continue Reading Genetic diversity of loquat (Eriobotrya japonica) revealed using RAD-Seq SNP markers & More Science News

ERROR No such moleculetype NA – User discussions

GROMACS version:GROMACS modification: Yes/No I got this errorwhen I run the line: gmx grompp -f em.mdp -c solv_ions.gro -p topol.top -o em.tpr -maxwarn 10in the topol.top there is 3 NA atoms 🙂 GROMACS – gmx grompp, 2020.1-Ubuntu-2020.1-1 (-: GROMACS is written by: Emile Apol Rossen Apostolov Paul Bauer Herman J.C….

Continue Reading ERROR No such moleculetype NA – User discussions

How a genetic mutation affects the body’s immune system response to viruses, development of blood cancers

Graphical abstract. Credit: Cell Reports (2022). DOI: 10.1016/j.celrep.2022.110856 The body’s innate immune system, active from birth, is the first line of defense against viruses and other pathogens that cause disease. Using vaccination as an example, after receiving a vaccine, pain, redness, or swelling may occur at the injection site. This…

Continue Reading How a genetic mutation affects the body’s immune system response to viruses, development of blood cancers

TMEM151A Variants Cause Paroxysmal Kinesigenic Dyskinesia (PKD)

Paroxysmal dyskinesia is the most prevalent kind of paroxysmal kinesigenic dyskinesia (PKD). Proline-rich transmembrane protein 2 (PRRT2) mutations are responsible for just one-third of PKD patients. For a study, researchers sought to look for a possible PKD causal gene. A total of 196 PRRT2-negative PKD patients were included in the…

Continue Reading TMEM151A Variants Cause Paroxysmal Kinesigenic Dyskinesia (PKD)

tReasure: R-based GUI package analyzing tRNA expression profiles from small RNA sequencing data | BMC Bioinformatics

tReasure (tRNA Expression Analysis Software Utilizing R for Easy use) is a graphical user interface (GUI) tool for the analysis of tRNA expression profiles from deep-sequencing data of small RNAs (small RNA-seq) using R packages. The whole analysis workflow, including the uploading of FASTQ files of small RNA-seq, quantification of…

Continue Reading tReasure: R-based GUI package analyzing tRNA expression profiles from small RNA sequencing data | BMC Bioinformatics

Long-term artificial selection of Hanwoo (Korean) cattle left genetic signatures for the breeding traits and has altered the genomic structure

Cattle are among the largest populations of domesticated animals and used as food resources for humans; therefore, their phenotypes and genetic structure have been shaped by artificial selection for human needs and natural adaptation to environmental changes. The phenotypic selection causes genomic changes in breeding traits within breeds, resulting in…

Continue Reading Long-term artificial selection of Hanwoo (Korean) cattle left genetic signatures for the breeding traits and has altered the genomic structure

Medical Alert System/Personal Emergency Response System Market Size And Forecast

New Jersey, United States – Medical Alert System/Personal Emergency Response System Market Research Report provides you with detailed and accurate analysis to strengthen your position in the market. It provides the latest updates and powerful insights on the Medical Alert System/Personal Emergency Response System industry to help you improve your business…

Continue Reading Medical Alert System/Personal Emergency Response System Market Size And Forecast

Bioconductor – DaMiRseq (development version)

DOI: 10.18129/B9.bioc.DaMiRseq     This is the development version of DaMiRseq; for the stable release version, see DaMiRseq. Data Mining for RNA-seq data: normalization, feature selection and classification Bioconductor version: Development (3.15) The DaMiRseq package offers a tidy pipeline of data mining procedures to identify transcriptional biomarkers and exploit them…

Continue Reading Bioconductor – DaMiRseq (development version)

Gilead’s CD47 clinical hold expands as CEO O’Day expresses ‘sense of urgency’ in getting trials back on track

Gilead revealed that a partial clinical hold for its CD47 targeted cancer hopeful is larger than originally thought. Last week, the California-based biotech shared that a handful of trials for magrolimab in combination with azacytidine had been placed on a partial clinical hold because of an “apparent imbalance” in adverse reactions…

Continue Reading Gilead’s CD47 clinical hold expands as CEO O’Day expresses ‘sense of urgency’ in getting trials back on track

Failure to detect mutations in U2AF1 due to changes in the GRCh38 reference sequence

Materials and Methods Genomic data was collected as part of the MDS National History Study or The Cancer Genome Atlas project and consented appropriately under those protocols 8 Sekeres M.A. Gore S.D. Stablein D.M. DiFronzo N. Abel G.A. DeZern A.E. Troy J.D. Rollison D.E. Thomas J.W. Waclawiw M.A. Liu J.J….

Continue Reading Failure to detect mutations in U2AF1 due to changes in the GRCh38 reference sequence

The role of ATXR6 expression in modulating genome stability and transposable element repression in Arabidopsis

Significance The plant-specific H3K27me1 methyltransferases ATXR5 and ATXR6 play integral roles connecting epigenetic silencing with genomic stability. However, how H3K27me1 relates to these processes is poorly understood. In this study, we performed a comprehensive transcriptome analysis of tissue- and ploidy-specific expression in a hypomorphic atxr5/6 mutant and revealed that the…

Continue Reading The role of ATXR6 expression in modulating genome stability and transposable element repression in Arabidopsis

Comprehensive, hands-on tutorial for DNA-ligand MDS – User discussions

GROMACS version: 2021.4-HomebrewGROMACS modification: No Hello, guys. I am very new to molecular dynamics and I come from biomedical background. Recently, my boss asked me to gather additional data about interaction of a small molecule and an aberrant double-stranded DNA structure. I originally did docking experiments in Vina, and he…

Continue Reading Comprehensive, hands-on tutorial for DNA-ligand MDS – User discussions

Celyad Oncology Presents Updates on shRNA-Based CAR T

Data continues to support the versatile potential of non-gene edited shRNA technology with updates from the CYAD-02 and CYAD-211 clinical programs Management to host conference call today December 13th at 2:30 p.m. CET / 8:30 a.m. EST MONT-SAINT-GUIBERT, Belgium, Dec. 13, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext &…

Continue Reading Celyad Oncology Presents Updates on shRNA-Based CAR T

Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

Oral and Poster Abstracts 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III Translational Research Maher Albitar, MD1*, Andrew Ip, MD, MSc2, Andre H. Goy, MD3*, Jeffrey Justin Estella, BS, MS1*, Ivan De Dios, BS1*,…

Continue Reading Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

Single-cell DNA and RNA sequencing reveals the dynamics of intra-tumor heterogeneity in a colorectal cancer model | BMC Biology

Organoid culture of small intestinal cells and lentiviral transduction C57BL/6J mice and BALB/cAnu/nu immune-deficient nude mice were purchased from CLEA Japan (Tokyo, Japan). The small intestine was harvested from wild-type male C57BL/6J mice at 3–5 weeks of age (Additional file 1: Figure S9A). Crypts were purified and dissociated into single cells,…

Continue Reading Single-cell DNA and RNA sequencing reveals the dynamics of intra-tumor heterogeneity in a colorectal cancer model | BMC Biology

Genetic Testing for Parkinson’s Is Costly, Hard to Access, Survey Shows

High prices, lack of access, and long waiting times are major barriers to people who want to undergo genetic testing for Parkinson’s disease, according to a survey by the International Parkinson and Movement Disorder Society (MDS). Survey results will be presented at the MDS Virtual Congress 2021, held online Sept. 17–22,…

Continue Reading Genetic Testing for Parkinson’s Is Costly, Hard to Access, Survey Shows